1461092740-9c574703-3d6e-4a10-bcb6-7eac87b50472

1. A method for the treatment or reduction in the incidence or severity of clinical signs caused by Lawsonia intracellularis, Salmonella choleraesuis, and Erysipelothrix rhusiopathiae, said method comprising the steps of:
administering a composition containing antigenic components, wherein the antigenic components consist essentially of attenuated modified live Lawsonia intracellularis, an immunological active component of Salmonella choleraesuis, and an immunological active component of Erysipelothrix rhusiopathiae, to a non-human animal in need thereof, wherein said administration results in the treatment or reduction of clinical signs of Lawsonia intracellularis, Salmonella choleraesuis, and Erysipelothrix rhusiopathiae.
2. The method of claim 1, wherein said attenuated modified live Lawsonia intracellularis, said immunological active component of Salmonella choleraesuis, and said immunological active component of Erysipelothrix rhusiopathiae are administered on the same day.
3. The method of claim 1, wherein said attenuated modified live Lawsonia intracellularis, said immunological active component of Salmonella choleraesuis, and said immunological active component of Erysipelothrix rhusiopathiae are administered at the same time.
4. The method of claim 1, wherein at least two of said attenuated modified live Lawsonia intracellularis, said immunological active component of Salmonella choleraesuis, and said immunological active component of Erysipelothrix rhusiopathiae are combined together prior to administration thereof.
5. The method of claim 1, wherein said clinical signs include lesions caused by Lawsonia intracellularis, lesions caused by Erysipelothrix rhusiopathiae, and clinical signs caused by virulent Salmonella cholaraesuis.
6. The method of claim 1, wherein said attenuated modified live Lawsonia intracellularis is effective for reducing the incidence of or lessening the severity of porcine proliferative enteropathy caused by Lawsonia intracellularis.
7. The method of claim 1, wherein said immunological active component of Salmonella choleraesuis further comprises attenuated Salmonella choleraesuis and wherein said attenuated Salmonella choleraesuis is effective for reducing the incidence of or lessening the severity of infections caused by Salmonella choleraesuis.
8. The method of claim 1, wherein said immunological active component of Erysipelothrix rhusiopathiae further comprises attenuated Erysipelothrix rhusiopathiae and wherein said attenuated Erysipelothrix rhusiopathiae is effective for reducing the incidence of or lessening the severity of infections caused by Erysipelothrix rhusiopathiae.
9. The method of claim 1, wherein said composition further comprises a veterinary-acceptable carrier.
10. The method of claim 9, wherein said veterinary-acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and combinations thereof.
11. A method for treating or reducing the incidence or severity of clinical signs of diseases caused by Lawsonia intracellularis and two or more further swine pathogenic microorganisms, said two or more further swine pathogenic microorganisms including Salmonella choleraesuis and Erysipelothrix rhusiopathiae, said method comprising the steps of:
administering a composition containing antigenic components, where the antigenic components consist essentially of avirulent modified live Lawsonia intracellularis to a non-human animal in need thereof together with an immunological active component of Salmonella choleraesuis and an immunological active component of Erysipelothrix rhusiopathiae, to an animal in need thereof, wherein said administration results in the treatment or reduction in the incidence or severity of clinical signs of Lawsonia intracellularis, Salmonella choleraesuis, and Erysipelothrix rhusiopathiae.
12. The method of claim 11, wherein said administration of said avirulent modified live Lawsonia intracellularis, said immunological active component of Salmonella choleraesuis and said immunological active component of Erysipelothrix rhusiopathiae occurs on the same day.
13. The method of claim 11, wherein said administration of said avirulent modified live Lawsonia intracellularis, said immunological active component of Salmonella choleraesuis and said immunological active component of Erysipelothrix rhusiopathiae occurs at the same time.
14. The method of claim 11, wherein at least two of said avirulent modified live Lawsonia intracellularis, said immunological active component of Salmonella choleraesuis and said immunological active component of Erysipelothrix rhusiopathiae are combined together prior to said administration.
15. The method of claim 11, wherein said clinical signs include lesions caused by Lawsonia intracellularis, lesions caused by Erysipelothrix rhusiopathiae, and clinical signs caused by virulent Salmonella cholaraesuis.
16. The method of claim 11, wherein said avirulent modified live Lawsonia intracellularis is effective for reducing the incidence of or lessening the severity of porcine proliferative enteropathy caused by L. intracellularis.
17. The method of claim 11, wherein said immunological active component of Salmonella choleraesuis further comprises attenuated Salmonella choleraesuis and wherein said attenuated Salmonella choleraesuis is effective for reducing the incidence of or lessening the severity of infections caused by Salmonella choleraesuis.
18. The method of claim 11, wherein said immunological active component of Erysipelothrix rhusiopathiae further comprises attenuated Erysipelothrix rhusiopathiae and wherein said attenuated Erysipelothrix rhusiopathiae is effective for reducing the incidence of or lessening the severity of infections caused by Erysipelothrix rhusiopathiae.
19. The method of claim 11, wherein said composition further comprises a veterinary-acceptable carrier.
20. The method of claim 1, wherein said veterinary-acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and combinations thereof.
21. A method for the treatment or reduction in the incidence or severity of clinical signs caused by Lawsonia intracellularis, Salmonella choleraesuis, and Erysipelothrix rhusiopathiae, said method consisting essentially of the steps of:
administering a composition containing antigenic components, wherein the antigenic components consist essentially of attenuated modified live Lawsonia intracellularis, an immunological active component of Salmonella choleraesuis, and an immunological active component of Erysipelothrix rhusiopathiae to a non-human animal in need thereof, wherein said administration results in the treatment or reduction of clinical signs of Lawsonia intracellularis, Salmonella choleraesuis, and Erysipelothrix rhusiopathiae.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A bottom-emitting vertical cavity surface emitting laser, comprising:
a substrate permitting the passage of light therethrough.
a laser stack consisting essentially of a high reflectivity mirror, a low reflectivity mirror; and an active light-amplifying region located between said high and low reflectivity mirrors, said laser stack being provided on said substrate with said low reflectivity mirror adjacent said substrate;
a light output port located in said substrate adjacent said low reflectivity mirror for transmitting light emitted by said active light-amplifying region and constituting an output of said laser; and
an ohmic contact provided on said high reflectivity mirror, said ohmic contact being photon transparent for transmitting some of said light emitted by said light-amplifying region that passes through said high reflectivity mirror for monitoring with an external photodetector.
2. A surface emitting cavity laser as claimed in claim 1, wherein said ohmic contact is made of a photon transparent material.
3. A surface emitting cavity laser as claimed in claim 2, wherein said photon transparent material comprises Indium Tin Oxide.
4. A surface emitting cavity laser as claimed in claim 1, wherein said ohmic contact contains an aperture to pass light there through.
5. A surface emitting cavity laser as claimed in claim 1, wherein said ohmic contact has a thickness between 1 and 100 nm.
6. A surface emitting cavity laser as claimed in claim 1, wherein, said output port is provided by a hole in said substrate.
7. A surface emitting cavity laser as claimed in claim 6, wherein said ohmic contact is made of a photon transparent material.
8. A surface emitting cavity laser as claimed in claim 7, wherein said photon transparent material comprises Indium Tin Oxide.